The correlation between levels of sPD-L1 and clinical outcome of mesothelioma patients enrolled in the NIBIT-MESO-1 clinical trial was investigated to assess the potential role of sPD-L1 as a predictive biomarker of response to ICI therapy. This evidence concerns the gene SPDL1 and mesothelioma.